FWIW - both glaucoma inserts on the market, the second having just been approved, have a label restriction disallowing use more than once in an eye. For at least Durysta this was not the original plan; it just showed up in the later/bigger trials that repeated use showed problems. My point is that this was not obvious in the earlier/smaller trials that are more like this OCUL one, and I haven’t yet seen strong data on what small trial, single use proxies accurately predict that reuse risk in the later ph3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.